The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for industry and patients. Our two companies are applying AI in ...
Commissioner Martin Makary and the outgoing director of the Center for Biologics Evaluation and Research (CBER) Vinay Prasad published an article in The New England Journal of Medicine,[1] in which ...
Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...
The Food and Drug Administration (FDA) development and approval process for drugs and medical devices involves multiple phases that ensure the safety and effectiveness of products before and after ...
FRANKFURT, Germany--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, will showcase its latest flexible solutions to help boost efficiency and scale in ...
Business leaders must understand what patient-centric care really requires. Too often, patients, researchers and investors ...
A stylized image of Max Barnhart sitting on a chair with his arm on a pillow, receiving an IV infusion. The background is a grid containing a microscope image of malaria parasites flanked on each side ...
The US Food and Drug Administration (FDA) wants the public's feedback on ways it can make it easier to communicate with the agency during the clinical trials process. In an announcement in the Federal ...
Adial Pharmaceuticals Inc. ADIL said Wednesday it has completed demonstration batch production for its lead candidate AD04, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results